Explained: How coronavirus has disrupted access to Parkinson’s medication

The responses indicated that 88.9 per cent of those in low-income countries considered access to Parkinson’s disease medication to have been affected by Covid-19, compared with 22.8 per cent of those in high income countries.

All of the surveyed health professionals in low-income countries indicated that this would result in increased disability.

Resource-poor countries appear to be disproportionately affected compared with more affluent countries. Patients from high income countries in East Asia, Europe and North America were less affected.

Source: Queen Mary University of London